Menlo therapeutics inc. (MNLO)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15
EXPENSES
Collaboration and license revenue

-

10,640

4,582

674

-

Collaboration and license revenue

-

-

-

-

0

Operating expenses:
Research and development

53,761

52,989

29,007

11,255

2,921

General and administrative

22,481

12,186

5,168

3,751

1,687

Total operating expenses

76,242

65,175

34,175

15,006

4,608

OPERATING LOSS

-76,242

-54,535

-29,593

-14,332

-4,608

Interest income and other expense, net

2,539

3,090

517

264

-

Interest income and other expense, net

-

-

-

-

0

NET LOSS FOR THE PERIOD

-73,703

-51,445

-29,076

-14,068

-4,608

Other comprehensive loss:
Unrealized gain (loss) on available-for-sale securities

120

-45

-25

-26

0

Comprehensive loss

-73,583

-51,490

-29,101

-14,094

-4,608

LOSS PER SHARE BASIC AND DILUTED (in USD per share)

-3.09

-2.37

-5.69

-2.82

-0.97

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE IN THOUSANDS (in shares)

23,818

21,668

5,108

4,987

4,735